Know Cancer

forgot password

Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy

Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy

This study addresses three major sources of post-implant dosimetry inaccuracy for permanent
prostate implants: post-operative edema, prostate contour delineation, and dose calculation
method. It is hypothesized that a pragmatic edema model can minimize the first
uncertainty, co-registered CT + MR images the second, and an improved dose calculation
algorithm the third.

Detailed objectives are to:

- measure and model the effects of edema on dosimetry;

- evaluate CT + MR image registration methods;

- compare dosimetry for CT alone vs. CT + MRI using the contemporary TG-43 dose
calculation method;

- set up a Monte Carlo code that makes full use of the information in CT + MR images to
perform implant dose calculations;

- compare prostate dosimetry for the Monte Carlo vs. the simpler TG-43 method;

- develop an analytical post-implant dose calculation algorithm for routine clinical use
(Monte Carlo is too slow on a single-CPU brachytherapy planning computer); and finally

- assess the performance of the new algorithm.

Of the estimated 250,000 new cases of prostate cancer in North America in 2004, most are
early stage disease as a consequence of PSA testing. Permanent prostate implant therapy is
a major option for this group, as long-term clinical studies indicate a cure rate equal to
surgery and external beam radiotherapy, but with fewer complications. By dealing with
dosimetric inaccuracies, a proven treatment can reach its full potential.

Inclusion Criteria:

- Candidate for permanent prostate implant

Exclusion Criteria:

- Not ambulatory

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

implant dose coverage at 4 weeks, comparing CT and MRI versus CT alone

Principal Investigator

Ron Sloboda, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Health Services


Canada: Health Canada

Study ID:

SP-14-0044 / 21694



Start Date:

April 2005

Completion Date:

December 2012

Related Keywords:

  • Prostate Cancer
  • brachytherapy
  • implant radiotherapy
  • Prostatic Neoplasms